Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
11,341 total articles
Insulet (PODD) has been punished after an FDA-classified high-risk recall of certain Omnipod 5 pods. The sell-off prices in a short-term demand shock while the company still shows healthy fundamentals: $10.9B market cap, positive free cash flow of $399.9M, ROE ~23%, and manageable leverage. This trade idea outlines a mid-term (45 trading days) long…
Akamai is trading near its 52-week high after accelerating momentum in cloud and security sales. With a $1.8B Anthropic cloud deal announced in early May and a cash-generative business (free cash flow $854.9M), the company has the financial firepower and product footprint to reaccelerate growth. Valuation is rich at ~50x trailing earnings, so this …
Fresh Del Monte (FDP) is trading below its 50-day and 20-day averages on an oversold RSI while still generating strong free cash flow and paying a healthy dividend. With a market cap around $1.68B, EV/EBITDA of 8.3, and free cash flow of $174.9M, the stock looks attractively valued for a measured buy-the-dip trade over the next 45 trading days.
SanDisk (SNDK) is benefiting from secular AI-driven NAND demand and a defensive capital structure. The name looks tradeable on a disciplined long with an entry at $1454.88, stop at $1350.00, and an initial target of $1600.00 over a mid-term exposure window. The setup balances near-term volatility with multi-quarter secular tailwinds backed by cash …
ACNB trades near $52.80 and offers an attractive earnings multiple, a raised quarterly dividend plus a special payout and a fresh buyback authorization; we like the risk/reward for a long-term (180 trading days) trade with a $60 target and a tight stop below $49.
Meta Platforms trades at $605.37 with a $1.535T market cap, strong free cash flow and high profitability. Technicals show recent weakness, but average daily liquidity and low days-to-cover, combined with reports of low put-call ratios in the options market, create an asymmetric trade: buy mid-dated calls for a measured upside target of $675 with a …
Micron looks less like a cyclical commodity and more like a competitively advantaged supplier of specialized memory for AI infrastructure. Strong revenue acceleration, robust free cash flow, low leverage and sold-out supply for 2026 support continued upside, but stretched multiples and outsized market moves demand tight risk management.
Meta is at a fork: convert its ad platform and massive user graph into higher-priced, AI-driven ad products and enterprise services, or limp through another cycle where infrastructure and Reality Labs spending sap margins. I outline a swing trade that leans long, with a clear entry, stop and target based on valuation, cash flow and technicals.
Beam's clinical progress with BEAM-302 and a $500M milestone-backed facility have shifted the investment case from speculative platform upside to a calendar-driven regulatory asset story. Current valuation already prices some upside, but the risk/reward favors a long position into pivotal cohort initiation and potential accelerated approval signali…
Baycurrent is positioned as a Japan-focused digital transformation (DX) services provider with deep enterprise relationships and high recurring service mix. Financial detail coverage was limited in the materials available to me, but the company’s business model, client base, and margin levers make a mid-term long trade attractive. Entry at $6.50, s…
Gilead is morphing from a steady antiviral cash engine into a diversified biotech platform focused on long-duration oncology and protein-degradation partnerships. With a market cap near $165B, $10.2B in free cash flow and a 2.36% dividend yield, the stock offers a risk-reward where selective long exposure captures upside from pipeline licensing, da…
Micron (MU) is positioned to capture accelerated DRAM and HBM demand from generative AI infrastructure. This trade idea outlines a long entry at $140.00 with a $225.00 target and a $95.00 stop, framed for a long-term holding period (180 trading days). The thesis rests on structural memory tightness, capacity discipline, and product mix improvement …
Strategy Inc (MSTR) is effectively a bitcoin treasury wrapped in equity. With roughly 818,334 BTC on the balance sheet valued at $64.14B and a market cap near $64.6B, the stock trades as a near one-for-one play on Bitcoin. For traders who prefer cash over headline volatility, we recommend a tactical short/realization trade: enter at $184.45, target…
Molson Coors (TAP) is trading near its 52-week low after a rough earnings cycle, but free cash flow of $1.17B, an EV/EBITDA of 6.6, and a 4.6% yield make it an asymmetric swing trade. This idea buys the volatility: entry at $41.34, stop at $38.00, primary target $47.00 (mid term) with a longer-term stretch to $55.00 if industry trends normalize.
The Hartford (HIG) trades at roughly $133 and offers a compelling free-cash-flow yield and healthy returns on equity, yet underwriting and revenue growth remain lumpy. This trade idea outlines a mid-term swing long that buys the cash-flow story while protecting against underwriting or macro-driven shocks.
On Holding (ONON) combines durable premium positioning in running and lifestyle footwear with recent margin upgrades and institutional accumulation. The stock is trading nearer its 52-week low while fundamental momentum and technical setups suggest asymmetric upside. This trade idea lays out entry, stop and targets for a long-term position over 180…
Sempra's exposure to Oncor and a reported 127 GW pipeline in Texas creates a levered growth story that the market is under-pricing. With market cap near $61B and EV around $96B, the stock at ~$93 offers upside if Oncor-related projects begin to monetize. We'll lay out an actionable long trade with an entry, stop and target, and the key catalysts an…
Rocket Lab (RKLB) is trading at premium multiples after a record Q1 print and a string of contracts. The shares look overbought technically, but a $2.2B backlog, rising revenue and a clear product roadmap (including the Neutron test in Q4 2026) give me enough conviction to upgrade to Buy with a disciplined entry, stop and target.
Advanced Micro Devices is pricing in rapid AI-driven revenue gains and already shows technical confirmation for another leg higher. Strong Q1 growth in data center and accelerating CPU adoption underpin the thesis, even as valuation is elevated. This is an actionable trade: enter on confirmation, size appropriately, and use a $420 stop to protect a…
Alphabet's core businesses are accelerating again—Google Cloud reported 63% growth and AI revenue jumped ~800% YoY—while the company sits on $64.4B of free cash flow and a $4.66T market cap. Technicals show bullish momentum, but elevated RSI and a potential analyst downgrade pose a near-term risk. This trade idea recommends a controlled long with d…
HUYA is trading below $3.25 despite a resilient business mix, growing engagement signals and a rising short interest that now looks crowded. With a $697M market cap, a demonstrable pattern of shareholder distributions and improving technical momentum, HUYA offers asymmetric upside into $4+ while keeping a tight stop below $2.60. This is a mid-term …
Alphabet (GOOG) is set up to capture AI demand across infrastructure, models, and apps through Google Cloud’s surge and a diversified, high-cash core. This trade targets participation in that multi-front AI story with defined risk controls and a 180-trading-day horizon.
Coherus Oncology (CHRS) is a low-priced, liquid oncology small-cap that recently raised $50.1M and carries a $264M market cap. The stock is trading well below its 52-week high and is heavily shorted, while management directs resources to commercialize LOQTORZI and advance clinical assets. We outline a mid-term trade (45 trading days) to capture pot…
CareTrust REIT (CTRE) remains a compelling buy after recent quarterly performance and portfolio moves. The REIT shows durable growth in revenue and FFO, a conservative balance sheet (debt/equity ~0.22) and a dividend yielding roughly 3.3%. I outline a clear trade: enter at $42.08, stop at $37.00, target $52.00 over a mid-term (45 trading days) hori…
Freshworks (FRSH) has been punished with a deep drawdown even as revenue growth and cash generation improved. At roughly $8.50, the stock offers an attractive entry for a long trade: reasonable near-term upside to $13 if growth stabilizes and sentiment recovers, with a tight stop below the 52-week low to limit downside risk.
